Physician profile
Michelle Mccain
NPI 1508867011
$3,115.08
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,273 · 2020: $883 · 2021: $959.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $756.15 | 2019-2021 | |
| Abbvie INC. | $493.96 | 2019-2021 | |
| Pfizer INC. | $351.26 | 2019-2021 | |
| Ucb, INC. | $306.37 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $194.13 | 2019 | |
| Janssen Biotech, INC. | $193.57 | 2019-2021 | |
| Lilly USA, LLC | $135.10 | 2019-2021 | |
| Horizon Therapeutics Plc | $130.91 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $122.28 | 2019-2021 | |
| Genentech USA, INC. | $108.64 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $59.73 | 2020-2021 | |
| Glaxosmithkline, LLC. | $56.71 | 2019-2020 | |
| Radius Health, INC. | $56.00 | 2019-2021 | |
| Genzyme Corporation | $54.92 | 2020-2021 | |
| Celgene Corporation | $29.70 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $17.84 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.75 | 2021 | |
| Mallinckrodt Enterprises LLC | $16.00 | 2019 | |
| Zyla Life Sciences, INC. | $15.06 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mccain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.